Get the Stockscreener App
4.58
4.58%
-0.22
After Hours:
4.99
0.41
+8.95%
Shattuck Labs Inc stock is traded at $4.58, with a volume of 1.11M.
It is down -4.58% in the last 24 hours and down -29.97% over the past month.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
See More
Previous Close:
$4.80
Open:
$4.952
24h Volume:
1.11M
Relative Volume:
1.85
Market Cap:
$351.20M
Revenue:
$1,000.00K
Net Income/Loss:
$-48.81M
P/E Ratio:
-5.9196
EPS:
-0.7737
Net Cash Flow:
$-39.95M
1W Performance:
-23.03%
1M Performance:
-29.97%
6M Performance:
+47.74%
1Y Performance:
+332.08%
1-Day Range:
$4.37
$5.17
1-Week Range:
$4.37
$5.995
52-Week Range:
$0.712
$8.33
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs Inc
Sector
Industry
Phone
512-900-4690
Address
500 W. 5TH STREET, AUSTIN
Compare STTK vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
4.58 | 368.07M | 1,000.00K | -48.81M | -39.95M | -0.7737 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-26 | Resumed | Needham | Buy |
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Dec-01-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-08-25 | Initiated | Wedbush | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-02-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-02-24 | Downgrade | Needham | Buy → Hold |
| Oct-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-31-22 | Initiated | BTIG Research | Buy |
| Jun-01-22 | Initiated | Citigroup | Buy |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Jan-11-21 | Initiated | Evercore ISI | Outperform |
| Nov-03-20 | Initiated | Citigroup | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Needham | Buy |
View All
Shattuck Labs Inc Stock (STTK) Latest News
Shattuck Labs to present Phase 1 SL-325 data on June 8 - scanx.trade
Shattuck Labs to present phase 1 data for SL-325 on Monday - Investing.com UK
Shattuck Labs to present phase 1 data for SL-325 on Monday By Investing.com - Investing.com South Africa
STTK Upgraded by Citigroup -- Rating Raised to Buy - GuruFocus
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8 - The Manila Times
Shattuck Labs to Present Phase 1 Clinical Data for SL-325 and Pipeline Update on June 8, 2026 - Quiver Quantitative
Shattuck Labs' High-Stakes Bet on a New Era for Autoimmune Treatment - BriefGlance
Shattuck Labs (STTK) Receives Upgrade and Catalyst Watch from Ci - GuruFocus
Citigroup Upgrades Shattuck Labs to Buy From Neutral, Price Target is $7 - marketscreener.com
Citigroup Upgrades Shattuck Labs to Buy From Neutral, Price Target Is $7 - Moomoo
Shattuck Labs (STTK) Receives Upgrade and Catalyst Watch from Citi - GuruFocus
Shattuck Labs, Inc. Amends and Restates 2020 Equity Incentive Plan – SEC 8-K Filing Details - Minichart
Shattuck Labs (STTK) director gets 81,000 stock options at $5.95 - Stock Titan
Shattuck Labs (STTK) director Neil Gibson receives 81,000 stock options at $5.95 - Stock Titan
Shattuck Labs (STTK) investors approve equity plan boost and annual say-on-pay - Stock Titan
Shattuck Labs (STTK) Slips 1.49% as Stock Nears Critical Support at $5.67Value Area Low - The Legal Advocate
STTK Q1 2026 Earnings: Narrower Loss Surprises as Biotech Advances PipelineManagement Guidance Update - The Legal Advocate
Director Clay B. Siegall doubles Shattuck Labs (STTK) holdings with warrant exercise - Stock Titan
Shattuck Labs (STTK) Holds Near Support as Biotech Sentiment ShiftsBearish Sentiment - The Legal Advocate
Shattuck Labs (STTK) Holds Steady at $6.1, Testing Familiar Support LevelsOBV Breakout - Newser
STTK Q1 2026 Earnings: Shattuck Labs Reports Narrower Loss, Beats EPS EstimatesEarnings Yield Analysis - The Legal Advocate
STTK Q1 2026 Earnings: Narrower Loss Surprises, No Revenue as Pipeline Progress ContinuesROIC Trend Report - newsline.com
STTK Q1 2026 Earnings: Narrower-than-expected loss highlights cost discipline amid pre-revenue stageAnnual Report - Newser
Number of shareholders of Shattuck Labs, Inc. – NASDAQ:STTK - TradingView
STTK Insider Buying: CTO Shukla Acquires 5,122 Shares on May 22, 2026 - Meyka
Shattuck Labs (NASDAQ: STTK) CTO exercises 5,122 warrants and increases share holdings - Stock Titan
Shattuck Labs: Priced As If Risk Was Not A Part Of The Equation (NASDAQ:STTK) - Seeking Alpha
Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation - Sahm
Officer at Shattuck Labs (NASDAQ: STTK) exercises warrants for 12,805 shares - Stock Titan
Shattuck Labs (STTK) Stock Analysis: -6.15% Loss — Key Levels 2026-05-15Social Trading Insights - newser.com
Shattuck Labs (STTK) Declines -6.15% Amid Market Weakness 2026-05-15Trading Community - newser.com
Shattuck Labs (STTK) Delivers Q1 2026 Beat — EPS $-0.13 vs $-0.14 ExpectedSpecial Dividend - newser.com
T. Rowe Price holds 9.87M shares of Shattuck Labs (NASDAQ: STTK) amendment - Stock Titan
Shattuck Labs CMO Pandite sells $198,300 in stock By Investing.com - Investing.com Nigeria
Insider Sell: Arundathy Pandite Sells 30,000 Shares of Shattuck Labs Inc (STTK) - GuruFocus
Shattuck Labs CTO Abhinav Shukla sells $14,244 in shares - Investing.com UK
Shattuck Labs CMO Pandite sells $198,300 in stock - Investing.com
Shattuck Labs CTO Abhinav Shukla sells $14,244 in shares By Investing.com - Investing.com Australia
[Form 4] Shattuck Labs, Inc. Insider Trading Activity - Stock Titan
Shattuck Labs (STTK) CMO sells 30K shares under 10b5-1 plan - Stock Titan
Shattuck Labs stock (US8124231002): Down 5.29% in May 2026 amid biotech volatility - AD HOC NEWS
Shattuck Labs (STTK) CEO exercises warrants to acquire 25,610 common shares - Stock Titan
Shattuck Labs (NASDAQ: STTK) executive reports 968-share tax withholding - Stock Titan
[144] Shattuck Labs, Inc. SEC Filing - Stock Titan
We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK), Novavax (NVAX) and Airsculpt Technologies (AIRS) - The Globe and Mail
STTK Maintained by Wedbush -- Price Target Raised to $11.00 - GuruFocus
Shattuck Labs Price Target Raised to $11.00/Share From $8.00 by Wedbush - Moomoo
Shattuck Labs Inc Stock (STTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Shattuck Labs Inc Stock (STTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shukla Abhinav A. | Chief Technical Officer |
May 12 '26 |
Sale |
7.01 |
2,032 |
14,244 |
81,258 |
| Pandite Arundathy N. | Chief Medical Officer |
May 12 '26 |
Sale |
6.61 |
30,000 |
198,300 |
166,219 |
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):